Regeneron Pharmaceuticals, Inc. (REGN) Q2 2024 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.29%

Regeneron's strong EPS performance, exceeding expectations by nearly 30%, led to a positive stock reaction, with shares rising 1.29%. The lack of revenue data and guidance leaves some uncertainty, but the management's optimistic tone suggests confidence in future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$11.56	N/A	+29.47%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific revenue figures or future guidance.

We are pleased with our EPS performance this quarter.

Our focus remains on innovation and delivering value to patients.

Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.29%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.29%

Key numbers

Management commentary